Amgen says FTC has ignored commitments it made to address Horizon deal concerns (update)
hapabapa/iStock Editorial via Getty Images
Update 6pm: Adds Amgen response to question in Q&A. 
Amgen (NASDAQ:AMGN) CEO Robert Bradway said the Federal Trade Commission has ignored the commitments that the company has made to address the regulator's concerns around its planned $28 billion purchase of Horizon Therapeutics (NASDAQ:HZNP). 
There are no competitive overlaps between the companies and no incentives to bundle Amgen's drugs with Horizon's, Bradway said on the company's Q2 earnings call on Thursday. 
"Simply put, there are no competitive overlaps and no incentives to bundle our drugs with theirs," Bradway said on the call. 
Horizon (HZNP) rose 1.7% in after hours trading on Thursday, while Amgen (AMGN) gained 1%.
Bradway said the company is working on integration plans with Horizon (HZNP) so the companies can combine by mid-December, when he expects the deal to close. 
When asked by an analyst if Amgen (AMGN) may consider renegotiating the deal price due to what he described as underperforming results for Tepezza, an Amgen executive said the company "remains enthusiastic about proceeding on the basis of the deal that we announced."
The comments come after Amgen (AMGN) and the FTC last month said there are no ongoing talks to try to come to a settlement over the antitrust regulators block of the Horizon deal. Both Amgen and the FTC said that there have been discussions in the past, according to a scheduling hearing with the FTC's Administrative Law Judge last month. The ALJ judge urged the parties to enter talks, and the companies said they were open to the possibility.
Amgen (AMGN) said in June it would not close the deal before Oct. 31 or the second business day after the court rules on the FTC's request to block the deal. U.S. District Judge John Kness set a hearing for September on the FTC's efforts to block the combination.
In June, CNBC's David Faber reported that Amgen (AMGN) and Horizon (HZNP) had talks with the FTC, though they didn't lead to a settlement.
Amgen (AMGN) agreed to acquire Horizon Therapeutics (HZNP) for $116.50 a share in cash in December, valuing the Ireland-based biotech at nearly $27.8 billion.
Horizon Therapeutics (HZNP) is scheduled to reports its Q2 results on Tuesday.
More on Horizon Therapeutics, Amgen

iRobot, Seagen, Horizon gain amid Microsoft win in Activision case
Six states join FTC lawsuit to block Amgen's planned purchase of Horizon
Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC
FTC Surprise Challenge Of Amgen's Acquisition Of Horizon Therapeutics